The popular and experimental drugs called peptides received unprecedented attention last month during a marathon hearing held by a panel that advises the Food and Drug Administration. Catherine Falls Commercial/Getty Images hide caption toggle caption Catherine Falls Commercial/Getty Images The peptide saga has reached what could be its most confusing chapter — at least for consumers. The popular — and experimental — drugs received unprecedented attention in late July during a marathon hearing held by a panel that advises the Food and Drug Administration. The panel considered whether to back the production of seven different peptide therapies — and voted in favor of all but one — despite concerns raised by the agency’s own scientists. These peptides include some of the most sought-after injectables, BPC-157, TB-500 and MOTS-c. But that recommendation alone doesn’t change the status of these substances. It’s still illegal for pharmacies in the U.S. to make these compounds. The FDA staff and leadership now need to review the data and decide whether compounding pharmacies in the U.S. should be allowed to make …